somascan®discovery

Whitepapers

whitepaper

Diabetes | Detection of low-abundance serum proteins associated with prediabetes for predictive and prognostic purposes

Diabetes mellitus refers to a family of metabolic disorders that are characterized by elevated blood glucose concentrations, or hyperglycemia. The International Diabetes Federation estimated that in 2015 there were 415 million diabetes cases worldwide in the 20-79 year old age group and predicted that number to increase to 640 million by 2040.

Read More »
whitepaper

Immuno-oncology | Circulating protein biomarkers are a promising avenue for predicting patient response to cancer immunotherapies

Cancer immunotherapy relies on activating or enhancing the antitumor immune response and has taken a central position in cancer treatment modalities. While offering a generally safer and more efficacious alternative to standard chemotherapy and radiotherapy, not all patients respond to immunotherapy, and combination immunotherapies increase cost of treatment and heighten the risk for toxicity-related adverse events. An understanding of the molecular factors that contribute to clinical outcomes could enable improved selection of subject cohorts; therefore, identifying predictive biomarkers of immunotherapy response has become a growing focus of immuno-oncology research.

Read More »
whitepaper

pQTL Analysis: the latest tool in disease research

Four letters, four compounds – adenine (A), cytosine (C), guanine (G), and thymine (T) – are the basic code “letters” of our genetic material, DNA. As elegant as the genetic code is, it is also quite dense with information, leading to many questions about how genetic variations affect our biology or health. How can the answers be found amongst all that tightly packed information?

Read More »
whitepaper

COVID-19 and the SomaScan® Platform

The battle against coronavirus disease 2019 (COVID-19) only begins with a test to identify who is infected and who is not. To accelerate an effective response, we have to move beyond the initial diagnosis to prognosis: Who is most susceptible to developing serious, life-threatening symptoms? Currently, there is no way to tell whether an infected individual (or an individual who may become infected) will be asymptomatic or require hospitalization. This wide variation in disease severity is, at least in part, a reflection of the myriad changes that occur within a person’s body as it fights the virus, which in turn reflect the unique biological makeup of that individual.

Read More »
whitepaper

CVD | Detection of low-abundance serum proteins associated with cardiovascular diseases for prognostic purposes

As the leading cause of death in the United States and worldwide, cardiovascular disease (CVD) includes a family of diseases that affect the heart and blood vessels. The primary origin of CVD is most often atherosclerotic in nature, in which fatty plaque deposits line arteries and obstruct circulation of blood. The etiology of CVD is multifactorial and is shaped by the interaction of genes and environment and further influenced by age and gender…

Read More »
whitepaper

NASH | Serum protein signatures as a non-invasive tool for monitoring nonalcoholic steatohepatitis

NASH and NAFLD are characterized by distinct sets of protein signatures. In our latest white paper, we discuss how researchers have used the SomaScan Assay to characterize and predict NASH non-invasively, even beating the best available clinical model. Download the white paper to learn more about how to get the most out of your NASH and NAFLD clinical samples with the world’s most impactful protein assay.

Read More »